GLP-1 Weight Loss Results by Medication: Visual Data Comparison
Interactive visual comparison of weight loss results across semaglutide, tirzepatide, and retatrutide from clinical trials and real-world data.
More on Data Visualization
Data Summary
Retatrutide leads with 24% body weight loss at 48 weeks, followed by tirzepatide at 21% and semaglutide at 15%. All three medications available through Trimi produce clinically meaningful weight loss.
Weight Loss by Medication Over Time
| Medication | Week 12 | Week 24 | Week 48 | Week 68 | Trial |
|---|---|---|---|---|---|
| Semaglutide 2.4mg | 5.9% | 10.3% | 15.2% | 16.9% | STEP 1 |
| Tirzepatide 15mg | 7.8% | 15.0% | 20.9% | 22.5% | SURMOUNT-1 |
| Retatrutide 12mg | 8.5% | 17.5% | 24.2% | TBD | Phase 2 |
Data from published clinical trials. Individual results vary. Percentages represent mean body weight reduction from baseline.
Visual Weight Loss Progression
Semaglutide 2.4mg
Tirzepatide 15mg
Retatrutide 12mg
What This Means in Real Numbers
Medical Disclaimer: Clinical trial data represents averages. Individual results vary based on starting weight, dose, adherence, diet, and exercise. This content is for informational purposes only.
Frequently Asked Questions
Which GLP-1 medication produces the most weight loss?
Based on clinical trial data, retatrutide (triple agonist) shows the highest weight loss at up to 24% body weight at 48 weeks. Tirzepatide follows at 20-22% (SURMOUNT trials), and semaglutide at 15-17% (STEP trials). Individual results vary significantly.
How quickly does weight loss begin?
Most patients see measurable weight loss within the first 4 weeks. The rate accelerates as doses are titrated upward. Peak weight loss velocity typically occurs between months 3-6, with results plateauing around 12-18 months.
Are clinical trial results realistic for real-world patients?
Real-world results tend to be slightly lower than clinical trials, averaging 10-15% for semaglutide and 15-20% for tirzepatide. This is still highly significant and life-changing for most patients.
Does weight loss continue indefinitely?
Weight loss typically plateaus at 12-18 months as the body reaches a new metabolic equilibrium. Maintenance dosing helps sustain the weight loss. Without continued medication, most patients regain 50-70% of lost weight within 1-2 years.
Start Your Weight Loss Journey
Compounded semaglutide from $99/mo or tirzepatide from $125/mo.
View Treatment OptionsSources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).